Korean Bioventure Financing Continues Downward Spiral In Q3
Handful Of IPOs Amid Chilly Sentiment
VC Investment in South Korea’s biopharma sector drops again as investors continue to shy away amid higher interest rates and reduced out-licensing deals.
You may also be interested in...
Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.
Several innovation-based Korean bioventures, including GI Innovation, S.Biomedics and Curocell, have managed to launch IPOs in 2023 despite prolonged depressed market sentiment and tougher stock exchange rules.
A policy report by a major South Korean pharma industry association puts forward suggestions on what it will take for a new pan-government control tower to function properly.